CTLA4 and neoplasm: In preclinical studies, blockade of CTLA-4 with antibodies against CTLA-4 enhanced the anti-tumor immunity by rejuvenating cytotoxic T-cells activity and also enhanced the response of tumors to high-dose hypofractionated irradiation [72,73,74,75].